NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies and ...
A cross-disciplinary team, led by the University of Glasgow, alongside the Universities of Nottingham and Strathclyde, will use pioneering technology ...